Thursday, March 28, 2013

Have you signed up for the Gross-to-Net Accounting Forum?

More and more, pharmaceutical manufacturers are realizing that nothing can be done in a vacuum. With something as complex and fundamental to an organization’s financial success as Gross-to-Net calculations, this need for collaboration is even more apparent. Before, commercial and government departments worked fairly independently, but those days are over.

At IIR’s Gross-to-Net Accounting Forum, we know how important it is to hear both sides of the GTN story – Commercial and Government. Our case studies will help you optimize accuracy and accountability over the entire pharmaceutical GTN process through internal government and commercial departmental collaboration. Case studies include:

● Account for the Government Pricing and Contracting Impact on GTN Calculations With Medicaid expansion continuing into 2014, the impact it has on pharmaceutical company financials is going to continue to grow. In this session, Jennifer Norton of Vertex Pharmaceuticals discusses how government pricing and calculations affect GTN and the operational changes in government pricing that arise that affect the overall calculation.

● Commercial Contracts and Gross-to-Net for Managed Care New legislation, new distribution channels and more complex contract structures continue to present operational challenges in managed care forecasting and accruals. In this session, Tara Brodo and Mila Tartakovsky of Daiichi Sankyo discuss process documentation, how to implement appropriate controls, and identifying risk and inefficiencies in the calculation process.

To find out more about the 2013 program, download the agenda.

As a reader of Healthcare Insights blog, you get a 15% discount off the standard rate when using code XP1811BLOG to register. If you have any questions about the agenda or event, please contact Kate Devery at or visit our webpage.

We look forward to seeing you this June!

The GTN Accounting Forum Team

Visit our homepage
Follow us on Twitter:
Join our Linkedin

No comments: